Анализ клинического течения хронических гастритов при проведении трехкомпонентной схемы эрадикации Helicobacter pylori с включением висмута трикалия дицитрата

Abstract

Purpose: to evaluate the dynamics of clinical manifestations of the disease in patients with chronic gastritis during the three-component treatment regimen of Helicobacter pylori with the inclusion of bismuthi trikalium dicitrate in the treatment. Material and methods. 38 residents of the Khanty-Mansi Autonomous Okrug-Ugra with chronic gastritis associated with Helicobacter pylori were examined in the Budgetary Establishment «Raduzhninskaya City Hospital». The clinical manifestations of dyspepsia and other manifestations of gastrointestinal dysfunction in patients before and after triple therapy with bismuthi trikalium dicitrate were evaluated. Statistical data processing was carried out using the program Statistica’ 99 Edition (Statsoft). The statistical significance of differences in different treatment periods was assessed using the Pearson – χ2 consent test and the Fisher test. The results. Clinical manifestations of the disease in the examined patients were represented by direct (58-84%) and complementary manifestations of dyspepsia (34-55%), manifestations of intestinal (32%), esophageal dysfunction (42%) in the presence of changes in general well-being (58%). When conducting eradication therapy, regression of direct manifestations of dyspepsia and heartburn is significant by the end of the first week of treatment, complementary criteria of dyspepsia – at the end of treatment. Manifestations of intestinal dysfunction in the form of constipation and discomfort in the mouth regress only 1 week after the end of therapy. Conclusion. The persistence of dyspepsia in 18% of cases after the end of eradication therapy is associated with the absence of eradication of Helicobacter pylori in 5% of cases and the functional origin of dyspepsia in 13% of cases. In patients with functional dyspepsia, the preservation of a low assessment of well-being according to the SAN questionnaire was verified, and in 5% of cases, the preservation of initial diarrhea after eradication therapy of Helicobacter pylori.